EdgarLookup

RANGE IMPACT, INC. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that RANGE IMPACT, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
15534.1%
Profit Margin
Net income ÷ revenue
12.9%
Return on Assets
Net income ÷ assets
3.98x
Debt-to-Equity
Total liabilities ÷ equity
-37.3%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2018 Mar 31, 2018 $102.4K Jun 28, 2018
FY2018 Mar 31, 2017 $163.4K Jun 28, 2018
FY2017 Mar 31, 2016 $248.3K Jun 28, 2017
FY2016 Mar 31, 2015 $245.7K Jun 24, 2016
FY2014 Mar 31, 2014 $0 Jun 30, 2014
FY2014 Mar 31, 2013 $0 Jun 30, 2014
FY2012 Mar 31, 2012 $0 May 20, 2013
FY2011 Mar 31, 2011 $0 Feb 15, 2013

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.03M Mar 31, 2026
FY2025 Sep 30, 2025 $569.9K Mar 31, 2026
FY2025 Jun 30, 2025 $1.11M Mar 31, 2026
FY2024 Dec 31, 2024 $579.8K Mar 31, 2025
FY2024 Sep 30, 2024 $2.17M Mar 31, 2025
FY2024 Jun 30, 2024 $2.35M Mar 31, 2025
FY2024 Mar 31, 2024 $3.91M Mar 31, 2025
FY2024 Dec 31, 2023 $6.88M Mar 31, 2025
FY2024 Sep 30, 2023 $5.46M Mar 31, 2025
FY2024 Jun 30, 2023 $4.00M Mar 31, 2025

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2024 Dec 31, 2024 ($361.1K) Mar 31, 2025
FY2024 Sep 30, 2024 ($392.9K) Mar 31, 2025
FY2024 Jun 30, 2024 ($148.9K) Mar 31, 2025
FY2024 Mar 31, 2024 $18.9K Mar 31, 2025
FY2024 Dec 31, 2023 $1.88M Mar 31, 2025
FY2024 Sep 30, 2023 $2.86M Mar 31, 2025
FY2024 Jun 30, 2023 $845.1K Mar 31, 2025
FY2024 Mar 31, 2023 $649.0K Mar 31, 2025
FY2023 Dec 31, 2022 $970.5K Aug 8, 2024
FY2023 Sep 30, 2022 $357.8K Aug 8, 2024

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $15.91M Mar 31, 2026
FY2025 Sep 30, 2025 ($813.0K) Mar 31, 2026
FY2025 Jun 30, 2025 ($1.03M) Mar 31, 2026
FY2025 Mar 31, 2025 $5.10M Mar 31, 2026
FY2025 Dec 31, 2024 ($2.44M) Mar 31, 2026
FY2025 Sep 30, 2024 ($4.92M) Mar 31, 2026
FY2025 Jun 30, 2024 ($1.23M) Mar 31, 2026
FY2025 Mar 31, 2024 ($1.21M) Mar 31, 2026
FY2024 Dec 31, 2023 ($83.0K) Mar 31, 2025
FY2024 Sep 30, 2023 $3.40M Mar 31, 2025

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($110.0K) Mar 31, 2026
FY2025 Sep 30, 2025 ($719.6K) Mar 31, 2026
FY2025 Jun 30, 2025 ($318.9K) Mar 31, 2026
FY2025 Mar 31, 2025 ($591.4K) Mar 31, 2026
FY2025 Dec 31, 2024 ($575.4K) Mar 31, 2026
FY2025 Sep 30, 2024 ($781.3K) Mar 31, 2026
FY2025 Jun 30, 2024 ($87.8K) Mar 31, 2026
FY2025 Mar 31, 2024 ($708.1K) Mar 31, 2026
FY2024 Dec 31, 2023 $124.0K Mar 31, 2025
FY2024 Sep 30, 2023 $1.66M Mar 31, 2025

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2023 Dec 31, 2023 $458.9K Aug 8, 2024
FY2023 Dec 31, 2022 $470.8K Aug 8, 2024
FY2022 Dec 31, 2021 $298.9K Mar 31, 2023
FY2021 Mar 31, 2021 $408.9K May 19, 2021
FY2021 Mar 31, 2020 $1.01M May 19, 2021
FY2020 Mar 31, 2019 $1.74M Jun 29, 2020
FY2019 Mar 31, 2018 $1.90M Jul 15, 2019
FY2018 Mar 31, 2017 $894.0K Jun 28, 2018
FY2017 Mar 31, 2016 $613.1K Jun 28, 2017
FY2016 Mar 31, 2015 $1.13M Jun 24, 2016

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $123.0K Mar 31, 2026
FY2025 Dec 31, 2024 ($1.59M) Mar 31, 2026
FY2024 Dec 31, 2023 $438.6K Mar 31, 2025
FY2023 Dec 31, 2022 ($603.8K) Aug 8, 2024
FY2022 Dec 31, 2021 ($1.37M) Mar 31, 2023
FY2021 Mar 31, 2021 ($1.61M) May 19, 2021
FY2021 Mar 31, 2020 ($3.59M) May 19, 2021
FY2020 Mar 31, 2019 ($3.67M) Jun 29, 2020
FY2019 Mar 31, 2018 ($2.89M) Jul 15, 2019
FY2018 Mar 31, 2017 ($1.38M) Jun 28, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2022 Dec 31, 2022 $5.81M Mar 31, 2023

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $123.24M Mar 31, 2026
FY2025 Dec 31, 2024 $6.19M Mar 31, 2026
FY2024 Dec 31, 2023 $23.79M Mar 31, 2025
FY2023 Dec 31, 2022 $8.23M Aug 8, 2024
FY2022 Dec 31, 2021 $50.9K Mar 31, 2023
FY2021 Mar 31, 2021 $896.8K May 19, 2021
FY2021 Mar 31, 2020 $2.57M May 19, 2021
FY2020 Mar 31, 2019 $6.08M Jun 29, 2020
FY2019 Mar 31, 2018 $675.8K Jul 15, 2019
FY2018 Mar 31, 2017 $1.18M Jun 28, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $85.45M Mar 31, 2026
FY2025 Dec 31, 2024 $5.36M Mar 31, 2026
FY2024 Dec 31, 2023 $14.22M Mar 31, 2025
FY2023 Dec 31, 2022 $5.29M Aug 8, 2024
FY2022 Dec 31, 2021 $432.6K Mar 31, 2023
FY2021 Mar 31, 2021 $33.4K May 19, 2021
FY2021 Mar 31, 2020 $1.28M May 19, 2021
FY2020 Mar 31, 2019 $1.05M Jun 29, 2020
FY2019 Mar 31, 2018 $353.5K Jul 15, 2019
FY2018 Mar 31, 2017 $800.7K Jun 28, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $21.46M Mar 31, 2026
FY2025 Dec 31, 2024 $834.4K Mar 31, 2026
FY2024 Dec 31, 2023 $9.57M Mar 31, 2025
FY2024 Dec 31, 2022 $2.94M Mar 31, 2025
FY2023 Dec 31, 2021 ($381.6K) Aug 8, 2024
FY2022 Mar 31, 2021 $863.4K Mar 31, 2023
FY2021 Mar 31, 2020 $1.28M May 19, 2021
FY2021 Mar 31, 2019 $5.02M May 19, 2021
FY2020 Mar 31, 2018 $322.3K Jun 29, 2020
FY2019 Mar 31, 2017 $374.4K Jul 15, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2023 $751.4K Mar 31, 2026
FY2024 Dec 31, 2022 $751.4K Mar 31, 2025

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($37.71M) Mar 31, 2026
FY2025 Dec 31, 2024 ($56.88M) Mar 31, 2026
FY2024 Dec 31, 2023 ($47.08M) Mar 31, 2025
FY2023 Dec 31, 2022 ($50.21M) Aug 8, 2024
FY2022 Dec 31, 2021 ($49.14M) Mar 31, 2023
FY2021 Mar 31, 2021 ($47.43M) May 19, 2021
FY2021 Mar 31, 2020 ($46.55M) May 19, 2021
FY2020 Mar 31, 2019 ($42.18M) Jun 29, 2020
FY2019 Mar 31, 2018 ($22.04M) Jul 15, 2019
FY2018 Mar 31, 2017 ($17.74M) Jun 28, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.11M Mar 31, 2026
FY2025 Dec 31, 2024 $167.3K Mar 31, 2026
FY2024 Dec 31, 2023 $2.18M Mar 31, 2025
FY2023 Dec 31, 2022 $442.4K Aug 8, 2024
FY2022 Dec 31, 2021 $38.3K Mar 31, 2023
FY2021 Mar 31, 2021 $884.1K May 19, 2021
FY2021 Mar 31, 2020 $2.39M May 19, 2021
FY2020 Mar 31, 2019 $5.98M Jun 29, 2020
FY2016 Mar 31, 2016 $95.4K Jun 24, 2016
FY2016 Mar 31, 2015 $389.7K Jun 24, 2016

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.80M Mar 31, 2026
FY2025 Aug 31, 2025 $914.8K Mar 31, 2026
FY2025 Nov 30, 2024 $1.01M Mar 31, 2026
FY2022 Dec 31, 2022 $5.06M Mar 31, 2023
FY2014 Mar 31, 2014 $0 Jun 30, 2014
FY2014 Mar 31, 2013 $580.4K Jun 30, 2014

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 31, 2026
FY2025 Sep 30, 2025 0 Mar 31, 2026
FY2025 Jun 30, 2025 0 Mar 31, 2026
FY2025 Mar 31, 2025 0 Mar 31, 2026
FY2025 Dec 31, 2024 0 Mar 31, 2026
FY2025 Sep 30, 2024 0 Mar 31, 2026
FY2025 Jun 30, 2024 0 Mar 31, 2026
FY2025 Mar 31, 2024 0 Mar 31, 2026
FY2024 Dec 31, 2023 0 Mar 31, 2025
FY2024 Sep 30, 2023 0 Mar 31, 2025

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Mar 31, 2026
FY2025 Sep 30, 2025 0 Mar 31, 2026
FY2025 Jun 30, 2025 0 Mar 31, 2026
FY2025 Mar 31, 2025 0 Mar 31, 2026
FY2025 Dec 31, 2024 0 Mar 31, 2026
FY2025 Sep 30, 2024 0 Mar 31, 2026
FY2025 Jun 30, 2024 0 Mar 31, 2026
FY2025 Mar 31, 2024 0 Mar 31, 2026
FY2024 Dec 31, 2023 0 Mar 31, 2025
FY2024 Sep 30, 2023 0 Mar 31, 2025

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 112.28M Mar 31, 2026
FY2025 Dec 31, 2024 104.73M Mar 31, 2026
FY2024 Dec 31, 2023 101.02M Mar 31, 2025
FY2023 Dec 31, 2022 78.12M Aug 8, 2024
FY2022 Dec 31, 2021 51.45M Mar 31, 2023
FY2021 Mar 31, 2021 50.84M May 19, 2021
FY2021 Mar 31, 2020 50.84M May 19, 2021
FY2020 Mar 31, 2019 52.29M Jun 29, 2020
FY2019 Mar 31, 2018 24.28M Jul 15, 2019
FY2018 Mar 31, 2017 22.22M Jun 28, 2018